Horizon Discovery announces collaboration with Novartis for X-MAN cell-lines
NVS | Quote | Chart | News | PowerRating -- Horizon Discovery, Ltd., a UK-based translational genomics company, has entered into a four year collaboration with Novartis AG, a Switzerland-based pharmaceutical company.
This is the second business agreement between Horizon and Novartis and and sees the use of Horizon's proprietary GENESIS(TM) gene-engineering platform to develop a broad panel of custom generated genetically-defined human 'X-MAN' cancer models for deployment in Novartis's drug discovery research programs.
Under this collaboration, Novartis will pay an upfront, milestone and renewal fees to Horizon.
Deal Type Partnership
Sub-Category Development
Deal Status Announced: 2009-11-17
Deal Participants
Partner 1 (Company) Horizon Discovery, Ltd.
Partner 2 (Company) Novartis AG
For full details on Novartis Ag Ads (NVS) NVS. Novartis Ag Ads (NVS) has Short Term PowerRatings at TradingMarkets. Details on Novartis Ag Ads (NVS) Short Term PowerRatings is available at This Link.
- Debiopharm Group signs agreement with Novartis for Debio 025 - 02/09/10
- SciClone and Sigma-Tau reports positive results from influenza vaccine study - 02/09/10
- Debiopharm Group signs licensing agreement with Novartis for Debio 025 for hepatitis C - 02/09/10
- Debiopharm Group Grants an Exclusive Licence for the Development, Manufacture and Commercialisation of Debio 025 - 02/09/10
- Novartis gains exclusive rights to Debio 025, an antiviral agent in Phase IIb development as potential first-in-class hepatitis - 02/09/10
- More News >>


